Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Haller

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Expert Review of Anticancer Therapy|July 19, 2018
Targeted therapy for metastatic colorectal cancerTimothy J Price, Monica Tang, Peter Gibbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJaffer A Ajani, Fa-Chyi Lee, Deepti A Singh, et al.
Mayo Clinic Proceedings|May 8, 2012
Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspectiveBernadette A Mansi, Juli Clark, Frank S David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) DatabaseManish A Shah, Lindsay A Renfro, Carmen J Allegra, et al.
Expert Review of Anticancer Therapy|August 21, 2014
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Timothy J Price, Eva Segelov, Matthew Burge, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Expert Review of Anticancer Therapy|March 19, 2020
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019David K Lau, Matthew Burge, Amitesh Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT databaseNadine J McCleary, Jeffrey A Meyerhardt, Erin Green, et al.
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
Expert Review of Anticancer Therapy|March 25, 2016
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Expert Review of Anticancer Therapy|July 19, 2018
Targeted therapy for metastatic colorectal cancerTimothy J Price, Monica Tang, Peter Gibbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJaffer A Ajani, Fa-Chyi Lee, Deepti A Singh, et al.
Mayo Clinic Proceedings|May 8, 2012
Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspectiveBernadette A Mansi, Juli Clark, Frank S David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) DatabaseManish A Shah, Lindsay A Renfro, Carmen J Allegra, et al.
Expert Review of Anticancer Therapy|August 21, 2014
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Timothy J Price, Eva Segelov, Matthew Burge, et al.
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.
Expert Review of Anticancer Therapy|March 19, 2020
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019David K Lau, Matthew Burge, Amitesh Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT databaseNadine J McCleary, Jeffrey A Meyerhardt, Erin Green, et al.
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
Expert Review of Anticancer Therapy|March 25, 2016
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, et al.
Pageof 12